$12.44
5.25% (Daily)
Market Cap
$913.31M
Revenue
$312.30M
Rank by MCap
#1809
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Randy Teel Ph.D.
Headquarters
New Haven, CT
Employees
430
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degrader...
Loading chart…